GLORIA

GEOMAR Library Ocean Research Information Access

Your email was sent successfully. Check your inbox.

An error occurred while sending the email. Please try again.

Proceed reservation?

Export
Filter
  • Future Medicine Ltd  (2)
Material
Publisher
  • Future Medicine Ltd  (2)
Language
Years
  • 1
    Online Resource
    Online Resource
    Future Medicine Ltd ; 2009
    In:  Future Oncology Vol. 5, No. 9 ( 2009-11), p. 1349-1361
    In: Future Oncology, Future Medicine Ltd, Vol. 5, No. 9 ( 2009-11), p. 1349-1361
    Abstract: High-grade gliomas and diffuse brainstem gliomas carry a very poor prognosis despite current therapies, and account together for the largest number of deaths in children with brain tumors. Many of these tumors have been found to overexpress the EGF receptor (EGFR). Nimotuzumab (h-R3) is a humanized monoclonal antibody against the EGFR, and consequently inhibits tyrosine kinase activation. In vitro and in vivo studies have supported the antiproliferative, antiangiogenic, pro-apoptotic and radiosensitizing activities of nimotuzumab. Emerging trials suggest a promising role for nimotuzumab as a therapeutic agent in patients with high-grade gliomas. This review attempts to provide a context for the evolving interest and evidence for nimotuzumab in pediatric glioma.
    Type of Medium: Online Resource
    ISSN: 1479-6694 , 1744-8301
    Language: English
    Publisher: Future Medicine Ltd
    Publication Date: 2009
    Location Call Number Limitation Availability
    BibTip Others were also interested in ...
  • 2
    Online Resource
    Online Resource
    Future Medicine Ltd ; 2013
    In:  CNS Oncology Vol. 2, No. 2 ( 2013-03), p. 143-159
    In: CNS Oncology, Future Medicine Ltd, Vol. 2, No. 2 ( 2013-03), p. 143-159
    Abstract: SUMMARY Optic pathway gliomas account for 3–5% of all pediatric CNS tumors and represent the most common intrinsic optic nerve tumors. These tumors occur preferentially during the first decade of life and are particularly frequent in children with neurofibromatosis type 1. Although optic pathway gliomas are low-grade tumors, their behavior can be aggressive, and their management is often challenging. Their management includes observation, surgery, chemotherapy and radiation. The role of each modality is discussed as well as current and future developments in treatment, in particular targeted therapies that are currently being investigated.
    Type of Medium: Online Resource
    ISSN: 2045-0907 , 2045-0915
    Language: English
    Publisher: Future Medicine Ltd
    Publication Date: 2013
    detail.hit.zdb_id: 2692808-5
    Location Call Number Limitation Availability
    BibTip Others were also interested in ...
Close ⊗
This website uses cookies and the analysis tool Matomo. More information can be found here...